Anti-inflammatory properties of cholinergic up-regulation: A new role for acetylcholinesterase inhibitors

被引:178
作者
Nizri, E [1 ]
Hamra-Amitay, Y [1 ]
Sicsic, C [1 ]
Lavon, I [1 ]
Brenner, T [1 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Ctr, Agnes Ginges Ctr Human Neurogenet, Dept Neurol,Lab Neuroimmunol, IL-91120 Jerusalem, Israel
关键词
acetylcholinesterase; acetylcholinesterase inhibitors; alpha 7 nicotinic receptor; CNS inflammation; experimental autoimmune encephalomyelitis; Alzheimer's disease;
D O I
10.1016/j.neuropharm.2005.10.013
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We investigated the anti -inflammatory effects of acetylcholinesterase inhibitors (AChEI) at the cellular and molecular levels. AChEI suppressed lymphocyte proliferation and pro-inflammatory cytokine production, as well as extracellular esterase activity. Anti-inflammatory activity was mediated by the alpha 7 nicotinic acetylcholine receptor (neuronal); the muscarinic receptor had the opposite effect. Treatment of the central nervous System (CNS) inflammatory disease, experimental autoimmune encephalomyelitis (EAE), with EN101 an anti-sense odeoxyrtucleotide tide, targeted to AChE mRNA, reduced the clinical severity of the disease and CNS inflammation intensity. The results of our experiments suggest that AChEI increase the concentration of extracellular acetylcholine (ACh), rendering it available for interaction with a nicotinic receptor expressed on lymphocytes. Our findings point to a novel role for AChEI which may be relevant in CNS inflammatory diseases such as EAE and multiple sclerosis. They also emphasize the importance of cholinergic balance in neurological disorders, such as Alzheimer's disease and myasthenia gravis, in which these drugs are used. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:540 / 547
页数:8
相关论文
共 38 条
[1]  
Barak V, 2002, ISR MED ASSOC J, V4, P919
[2]   Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin [J].
Borovikova, LV ;
Ivanova, S ;
Zhang, MH ;
Yang, H ;
Botchkina, GI ;
Watkins, LR ;
Wang, HC ;
Abumrad, N ;
Eaton, JW ;
Tracey, KJ .
NATURE, 2000, 405 (6785) :458-462
[3]   The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis [J].
Brenner, T ;
Hamra-Amitay, Y ;
Evron, T ;
Boneva, N ;
Seidman, S ;
Soreq, H .
FASEB JOURNAL, 2003, 17 (02) :214-222
[4]   Drug therapy - Alzheimer's disease [J].
Cummings, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (01) :56-67
[5]   Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats [J].
D'Intino, G ;
Paradisi, M ;
Fernandez, M ;
Giuliani, A ;
Aloe, L ;
Giardino, L ;
Calzà, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (08) :3070-3075
[6]  
Fujii T, 1996, J NEUROSCI RES, V44, P66, DOI 10.1002/(SICI)1097-4547(19960401)44:1<66::AID-JNR9>3.0.CO
[7]  
2-G
[8]   Upregulation of mRNA encoding the M5 muscarinic acetylcholine receptor in human T- and B-lymphocytes during immunological responses [J].
Fujii, T ;
Watanabe, Y ;
Inoue, T ;
Kawashima, K .
NEUROCHEMICAL RESEARCH, 2003, 28 (3-4) :423-429
[9]   YM905, a novel M3 antagonist, inhibits Ca2+ signaling and c-fos gene expression mediated via muscarinic receptors in human T cells [J].
Fujii, T ;
Kawashima, K .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 2000, 35 (02) :71-75
[10]   Complex host cell responses to antisense suppression of ACHE gene expression [J].
Galyam, N ;
Grisaru, D ;
Grifman, M ;
Melamed-Book, N ;
Eckstein, F ;
Seidman, S ;
Eldor, A ;
Soreq, H .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 2001, 11 (01) :51-57